NCT02791334: A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

NCT02791334
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: If not HR++/HER2-negative, must have MSI-H tumors
Exclusions: Participants with liver metastases; Participants with symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment
https://ClinicalTrials.gov/show/NCT02791334

Comments are closed.

Up ↑